CClinicalTrials.gg
Not yet recruitingNCT07350941RAP-ICUpdated Jan 20, 2026

Impact of Cardiac Rehabilitation Adapted for Patients With Heart Failure

An interventional study of Cardiac rehabilitation program in Heart Failure, sponsored by Puerta de Hierro University Hospital. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Puerta de Hierro University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate whether a tailored cardiac rehabilitation program, initiated during hospitalization and continued after discharge, can improve functional capacity, mobility, and quality of life in patients over 65 years old with heart failure.

Read the detailed description

If you meet the inclusion criteria and wish to participate, an initial assessment of your clinical and functional status will be conducted during your hospital stay. A computer system will then randomly assign you to one of the following groups:

Cardiac Rehabilitation Group (treatment group): You will participate in a mild exercise program during hospitalization (Phase I), including mobility and respiratory exercises adapted to your clinical condition. After discharge, you will enter a structured in-person cardiac rehabilitation program (Phase II) lasting 3 months, consisting of two 1-hour exercise sessions per week (aerobic, strength, inspiratory, and proprioceptive exercises) plus one weekly educational session.

Usual Care Group (control group): You will receive standard recommendations for physical activity and general care.

At the end of the study, a final consultation will be conducted to assess differences between the two groups in functional capacity and quality of life.

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Cardiac rehabilitation
  • Cardiopulmonary stress test
  • Functional capacity
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients hospitalized for acute heart failure in a stable phase (on a stable dose or tapering intravenous diuretics for at least 48 hours, without intravenous inotropes or vasodilators for >72 hours).
  • Baseline functional class II-III
  • Age ≥ 65 years
  • Able to walk >4 meters
  • Any range of left ventricular ejection fraction

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe dementia
  • Cardiac or other disease with a life expectancy \<12 months
  • Institutionalized patients or unable to travel to the rehabilitation center
  • Functional class I or IV
  • Uncontrolled arrhythmias
  • Inability to perform a basic exercise protocol
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Cardiac rehabilitation group (treatment group)

    3 months of a cardiac rehabilitation program, in which patients will attend in person twice weekly (Mondays and Wednesdays or Tuesdays and Thursdays), in groups of up to 8 patients, for 1-hour exercise sessions including aerobic, resistance, respiratory, and balance/proprioceptive components. Sessions will be monitored and supervised by cardiologists, rehabilitation physicians, and physiotherapists. In addition, patients will attend one weekly in-person educational session throughout the 3-month program.

    Other: Cardiac rehabilitation program

  • No intervention
    No intervention group

    General exercise and educational recommendations

Interventions

  • OtherCardiac rehabilitation program

    Cardiac rehabilitation program, in which patients will attend in person twice weekly (Mondays and Wednesdays or Tuesdays and Thursdays), in groups of up to 8 patients, for 1-hour exercise sessions including aerobic, resistance, respiratory, and balance/proprioceptive components. Sessions will be monitored and supervised by cardiologists, rehabilitation physicians, and physiotherapists. In addition, patients will attend one weekly in-person educational session throughout the 3-month program.

05

What researchers measure

Primary outcomes

  1. Primary Endpoint: Change in Peak Oxygen Uptake

    Change in peak oxygen uptake measured by treadmill cardiopulmonary exercise testing (peak VO₂, measured in ml/kg/min).

    Time frame: 3 months

Secondary outcomes

  1. Change in Functional Permormance assessed by the Short Physical Performance Battery (SPPB) score

    Change in the Short Physical Performance Battery (SPPB) score, ranging from 0 (worst physical performance) to 12 (best physical performance).

    Time frame: 3 months

  2. Change in the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) score

    Change in the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) overall summary score, ranging from 0 (worst health status) to 100 (best health status)

    Time frame: 3 and 6 months

  3. Change in distance walked (meters) in the 6-Minute Walk Test (6MWT).

    Change in distance walked (meters) in the 6-Minute Walk Test (6MWT).

    Time frame: 3 and 6 months

  4. Change in caregiver burden assessed by the Zarit scale

    Change in caregiver burden assessed by the 22-item Zarit Burden Interview (ZBI-22) score (range 0-88, with higher scores indicating greater caregiver burden)

    Time frame: 3 and 6 months

  5. Change in body composition parameters assessed by bioelectrical impedance analysis (BIA)

    Change in body composition parameters expressed as percentages (%), assessed by bioelectrical impedance analysis (BIA)

    Time frame: 3 and 6 months

  6. Number of participants experiencing all-cause mortality, heart failure decompensation, or heart failure-related hospitalization during follow-up

    All-cause mortality will be confirmed by medical records or death certificate. Heart failure decompensation will be defined as worsening of heart failure symptoms requiring urgent medical visit, treatment adjustment, or hospital admission. Heart failure-related hospitalizations will be collected from hospital records. Data will be aggregated as the number and percentage of participants experiencing each event during the study period

    Time frame: 3 and 6 months

  7. Change in Frailty status assessed by FRAIL scale

    Change in FRAIL scale (range 0-5, higher scores indicate greater frailty)

    Time frame: 3 and 6 months

  8. Change in emotional status assessed by the Hospital Anxiety and Depression Scale (HADS)

    Change in emotional status, measured using the Hospital Anxiety and Depression Scale (HADS), with subscales for anxiety and depression ranging from 0 to 21, where higher scores indicate greater symptom severity

    Time frame: 3 and 6 months

  9. Change in Nutritional Status assessed using the Mini Nutritional Assessment (MNA) score

    Change in nutritional status, assessed using the Mini Nutritional Assessment (MNA) score (range 0-30, with higher scores indicating better nutritional status)

    Time frame: 3 and 6 months

  10. Change in Maximal Inspiratory Pressure (MIP)

    Change in maximal inspiratory pressure (MIP) measured in cmH₂O, with higher values indicating greater respiratory muscle strength

    Time frame: 3 and 6 months

  11. Patient satisfaction

    Patient satisfaction with the cardiac rehabilitation program, rated from 0 to 10, being 10 the highest mark

    Time frame: 6 months

  12. Patient adherence

    Patient adherence to cardiac rehabilitation sessions, rated from 0 to 100%, being 100% the highest mark

    Time frame: 3 months

  13. Change in basic functional independence assessed by the Barthel Index

    Change in basic functional independence assessed by the Barthel Index (range 0-100, with higher scores indicating greater independence)

    Time frame: 3 and 6 months

  14. Change in maximal expiratory pressure (MEP)

    Change in maximal expiratory pressure (MEP) measured in cmH₂O, with higher values indicating greater respiratory muscle strength

    Time frame: 3 ad 6 months

06

Study locations

1 site
07

References and documents

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07350941
Lead sponsor
Puerta de Hierro University Hospital
Responsible party
Margarita Calvo López (Principal Investigator, Puerta de Hierro University Hospital) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 30, 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jan 20, 2026

Study contacts

Margarita Calvo-Lopez, MD
Contact
margarita.calvo@salud.madrid.org
+34637090285
Juan Carlos Lopez Azor, MD, PhD
Contact
lopez.gcia.juan.carlos@gmail.com
+34628026462
Margarita Calvo-LOpez, MD
principal investigator · Hospital Universitario Puerta de Hierro

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion